May 14, 1992—(Washington, DC) The Competitive Enterprise Institute today charged that FDA’s delay in approving Interleukin-2 may have cost as many as 3500 lives. IL-2 was finally approved last week as the only known therapy for metastic renal cell carcinoma, a fatal form of kidney cancer. Its application had been on file with the agency for three and a half years, since November 1988. During that time, it was approved in France, Demark, and seven other European countries.
You are here
Consumer Advocacy Group Attacks FDA for Slow Approval of Cancer Treatment